Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment

Abstract: Sustainable and safe delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate biodegradable poly(ethylene glycol)–poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NPs), which were surface-modified with lactoferrin (Lf), for efficient intranasal delivery of rotigotine to the brain for the treatment of PD. Rotigotine NPs were prepared by nanorecipitation, and the effect of various independent process variables on the resulting properties of NPs was investigated by a Box–Behnken experimental design. The physicochemical and pharmaceutical properties of the NPs and Lf-NPs were characterized, and the release kinetics suggested that both NPs and Lf-NPs provided continuous, slow release of rotigotine for 48 h. Neither rotigotine NPs nor Lf-NPs reduced the viability of 16HBE and SH-SY5Y cells; in contrast, free rotigotine was cytotoxic. Qualitative and quantitative cellular uptake studies demonstrated that accumulation of Lf-NPs was greater than that of NPs in 16HBE and SH-SY5Y cells. Following intranasal administration, brain delivery of rotigotine was much more effective with Lf-NPs than with NPs. The brain distribution of rotigotine was heterogeneous, with a higher concentration in the striatum, the primary region affected in PD. This strongly suggested that Lf-NPs enable the targeted delivery of rotigotine for the treatment of PD. Taken together, these results demonstrated that Lf-NPs have potential as a carrier for nose-to-brain delivery of rotigotine for the treatment of PD.

Keywords: rotigotine, lactoferrin-modified PEG-PLGA nanoparticles, brain targeting, intranasal delivery, Parkinson’s disease

Introduction
Parkinson’s disease (PD), the second most common neurodegenerative disorder in the world, manifests in approximately 1%–1.5% of individuals older than 60 years of age.1 Because of the aging population and longer life expectancy, the incidence of PD is expected to increase.2 Currently available antiparkinsonian drugs include dopamine agonists (eg, apomorphine), monoamine oxidase type B inhibitors and cholinesterase inhibitors (eg, donepezil).3 Among these drugs, the most commonly used is levodopa, which alleviates the symptoms and improves the quality of life of patients for several years. However, patients gradually develop tolerance to the therapeutic benefits of levodopa, and its use is related to some harmful side effects, including response fluctuations (wearing off) and levodopa-induced dyskinesia (LID).4,5 Therefore, novel strategies that focus on sustained drug release are required to decrease the occurrence of LID and attain continuous dopaminergic stimulation (CDS).6 Rotigotine was initially developed as an adjuvant treatment for early, secondary and advanced PD. It is a non-ergoline, enantioselective dopamine agonist, with preference for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
for $D_1 > D_2 > D_3$ receptors, which is considered to be of particular importance for its efficacy in PD. 

The blood–brain barrier (BBB) is composed of microvascular endothelial cells sealed by tight junctions. It plays a central role in regulating intra- and intercellular signaling pathways and maintaining central nervous system homeostasis, but it also restricts the delivery of therapeutic agents to the brain. To overcome this issue, a potential route is the direct transport of drugs from the nose to the brain via the olfactory and trigeminal nerve pathways, thereby bypassing the BBB. Over the past decades, research efforts have been reported on the design of nasal drug carriers for brain delivery, including nanoparticles (NPs), liposomes, microspheres and microemulsions.

Poly(ethylene glycol)–poly(lactic-co-glycolic acid) (PEG-PLGA) NPs constitute a promising strategy for brain-targeted delivery of rotigotine following intranasal administration. PEG-PLGA is biocompatible and biodegradable, and it has long-circulating behavior. NPs mask the physicochemical properties of drugs, in addition to providing controlled drug release, lower drug toxicity, as well as improved bioavailability, therapeutic efficacy and biodistribution. However, NPs contain surface PEG chains, which are likely to inhibit cell surface interactions. To achieve more efficient delivery from nose to brain, one approach is to modify NPs with biological ligands.

Lactoferrin (Lf) is a naturally occurring, iron-binding glycoprotein of the transferrin family, with a molecular weight of 80 kDa. Based on previous studies, the Lf receptor (LfR) is highly expressed on the apical surface of respiratory epithelial cells, as well as brain endothelial cells and neurons. Furthermore, LfR is overexpressed in the capillaries and neurons associated with age-related neurodegenerative diseases, including PD, Alzheimer’s disease and amyotrophic lateral sclerosis. Compared with transferrin (Tf) and OX-26, an anti-Tf receptor antibody, Lf displays higher brain uptake. Therefore, Lf may improve nose-to-brain delivery of NPs following intranasal administration.

Accordingly, the aim of this study was to prepare Lf-modified PEG-PLGA NPs (Lf-NPs) as a carrier for brain delivery of rotigotine, following intranasal administration for the treatment of PD. Experiments with mice and cells were conducted to evaluate the brain-targeting ability and toxicity of this system.

Materials and methods

Materials and animals

Bovine Lf, 2-iminothiolane (Traut’s reagent) and 5, 5’-dithiobis-(2-nitrobenzoic acid) (Ellman’s reagent) were purchased from Sigma-Aldrich (St Louis, MO, USA). Rotigotine was kindly provided by Luye Pharma Group (Shandong, People’s Republic of China). PEG-PLGA-maleimide (mal-PEG-PLGA; 3,400–20,000 Da, 50:50 LA:GA, w/w) and methoxy-PEG-PLGA (mPEG-PLGA; 2,000–20,000 Da, 50:50 LA:GA, w/w) were purchased from Polysciences (West Lafayette, IN, USA). Sephadex G25 and Sepharose CL-4B were purchased from GE Healthcare Bio-Sciences (Piscataway, NJ, USA). Furthermore, 1,1’-dioctadecyl-3,3’,3’-tetramethyldiethoxycarbocyanine iodide (DiR) and Hoechst 33342 were purchased from Fanbo Biochemicals Co (Beijing, People’s Republic of China); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent) and 3-(2’-benzothiazolyl)-7-diethylaminocoumarin (coumarin-6) were purchased from Aladdin Industrial Corp (Shanghai, People’s Republic of China). A bicinchoninic acid (BCA) protein quantitation kit was purchased from Beyotime Biotechnology (Shanghai, People’s Republic of China). All other reagents were of laboratory grade.

The cell lines 16HBE and SH-SY5Y and male Kunming (KM) mice (age: 4–5 weeks; weight: 20±2 g) were kindly provided by Luye Pharma Group (Shandong, People’s Republic of China). All animal studies were performed according to the Guide for the Care and Use of Laboratory Animals. The China Animal Care and Use Committee approved the study protocols.

Preparation of NPs and Lf-NPs

Preparation of NPs

Nanoprecipitation was used to prepare the NPs. In brief, accurately weighed mal-PEG-PLGA, mPEG-PLGA and rotigotine were dissolved in the organic phase (acetone) and then added dropwise into the aqueous phase under ice-cooling, with continued stirring to completely volatilize the organic solvent. The rotigotine NP was obtained. The same approach was applied for the coumarin-6 NP and DiR NP. All NPs were washed three times with ultrapure water, concentrated and collected by ultrafiltration.

Box–Behnken experimental design

To optimize the preparation process and to determine the impact of various factors on the encapsulation efficiency and particle size of NPs, a four-factor, two-level Box–Behnken design was used, based on preliminary experimental data. A total of 29 confirmatory formulation runs were generated with five center points using Design-Expert® software (version 8.0.6; Stat-Ease Inc, Minneapolis, MN, USA). Levels of the independent and dependent variables are shown...
in Table 1. The effect of the independent process variables on the dependent responses was studied using second-order polynomial equations.

Preparation of Lf-NPs
Lf was thiolated by reaction with a 20:1 M excess of 2-iminothiolane (Traut’s reagent) for 60 min, according to Huwyler’s method. The products were purified via a Sephadex G25 column. The quantity of introduced thiol groups was measured by ultraviolet (UV) spectrophotometry (λ=412 nm) (MetaSh Instruments Co, Ltd, Shanghai, People’s Republic of China) with Ellman’s reagent. To generate the Lf-NPs, purified, thiolated Lf was mixed with maleimide-functionalized NPs and incubated at room temperature for 9 h, enabling the maleimide groups to react with the thiol groups via a maleimide–thiol coupling reaction. The product was eluted with 0.01 M phosphate-buffered saline (PBS) buffer (pH 7.4) using a 1.5×20 cm Sepharose CL-4B column to remove the unconjugated protein. The concentration of protein and the protein conjugation efficiency were assessed with the BCA kit.

Characterization of NPs and Lf-NPs
Morphology, particle size and zeta potential
Morphological examinations of NPs were conducted by transmission electron microscopy (TEM) (H-600; Hitachi, Tokyo, Japan) following negative staining with sodium phosphotungstate solution (1%, w/v). The average particle size and zeta potential of the NPs were determined with a particle analyzer (Delsa Nano C; Beckman Coulter Inc, Brea, CA, USA).

Encapsulation efficiency and drug loading capacity
The encapsulation efficiency was determined by ultrafiltration. The samples were placed in an ultrafiltration device (100 kMWCO; Sartorius, Göettingen, Germany) and centrifuged at 3,500 rpm for 10 min at room temperature to isolate the free drug. The same volume of each sample was dissolved in acetonitrile to obtain the total amount of drug. The concentrations of rotigotine and coumarin-6 were measured with a high-performance liquid chromatography (HPLC) system (LC-20A VP system; Shimadzu, Kyoto, Japan), while the concentration of DiR was measured by UV spectrophotometry. The encapsulation efficiency and drug loading capacity of the NPs were calculated using the following equation:

\[
\text{Entrapment efficiency (\%)} = \frac{\text{Total amount of drug} - \text{Amount of free drug}}{\text{Drug dosage}} \times 100\%
\]

\[
\text{Drug loading (\%)} = \frac{\text{Total amount of drug} - \text{Amount of free drug}}{\text{Weight of NPs}} \times 100\%
\]

In vitro drug release study
Cellulose membrane dialysis tubing was used to investigate the release kinetics. In brief, 2 mL of NPs and Lf-NPs samples were encased in dialysis bags (molecular weight cutoff: 7 kDa), which were incubated in 30 mL phosphate buffer (pH 7.4) containing 0.5% (w/v) sodium dodecyl sulfate, with shaking in a water bath at 37°C. At prespecified time intervals, 1 mL of phosphate buffer was withdrawn from outside the dialysis bag, and an equivalent volume of release medium was supplemented. The rotigotine content was analyzed by HPLC at 223 nm. The amount of rotigotine released was calculated using a standard curve of rotigotine.

Cellular studies of NPs and Lf-NPs
Cell culture of SH-SY5Y and 16HBE cells
Cells of the human bronchial epithelial cell line 16HBE as well as SH-SY5Y cells, derived from the human neuroblastoma cell line SK-N-S, were incubated at 37°C and 5% CO₂ in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum, 100 IU/mL penicillin and 100 μg/mL streptomycin sulfate.

Cytotoxicity studies
The MTT assay was used to determine the cytotoxicity of NPs, Lf-NPs, rotigotine NPs and rotigotine Lf-NPs. The 16HBE cells and SH-SY5Y cells were seeded into a 96-well plate at a density of 10⁴ cells per well. After culturing for 24 h, the cells were treated with different concentrations of free rotigotine (12.5–200 μg/mL), or corresponding concentrations of rotigotine NPs or rotigotine Lf-NPs. The plates were incubated at 37°C in 5% CO₂ for either 24 h or 48 h, followed by 4 h exposure to 20 μL of MTT solution.

Table 1 Different levels of variables in the Box–Behnken design

<table>
<thead>
<tr>
<th>Variables</th>
<th>Levels</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Low</td>
<td>Medium</td>
<td>High</td>
</tr>
<tr>
<td>Independent variables</td>
<td></td>
<td>0.20</td>
<td>0.85</td>
<td>1.50</td>
</tr>
<tr>
<td>A</td>
<td>polymer concentration, mg/mL</td>
<td>5.00</td>
<td>10.00</td>
<td>15.00</td>
</tr>
<tr>
<td>B</td>
<td>aqueous/organic phase ratio</td>
<td>1.00</td>
<td>5.50</td>
<td>10.00</td>
</tr>
<tr>
<td>C</td>
<td>theoretical drug loading, %</td>
<td>0.00</td>
<td>1.00</td>
<td>2.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dependent variables</th>
<th>Desired constraints</th>
<th>Minimize</th>
<th>Maximize</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y₁</td>
<td>diameter of particles, nm</td>
<td>Minimize</td>
<td></td>
</tr>
<tr>
<td>Y₂</td>
<td>entrapment efficiency, %</td>
<td>Maximize</td>
<td></td>
</tr>
</tbody>
</table>

International Journal of Nanomedicine 2016:11

Submit your manuscript | www.dovepress.com | 6549

Dovepress

Intranasal delivery of rotigotine with lactoferrin-modified PEG-PLGA NPs

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 54.70.40.11 on 13-Dec-2018
For personal use only.
(5 mg/mL) per well. To solubilize the resultant formazan crystals, 200 μL of dimethyl sulfoxide was added to each well. Then, the absorbance of each well was measured at 570 nm after gentle shaking for 10 min.

**Cellular uptake of coumarin-6-labeled NPs and Lf-NPs**

Qualitative analyses of cellular internalization of coumarin-6-labeled NPs and Lf-NPs were performed using fluorescence microscopy (Eclipse E400; Nikon Corporation, Tokyo, Japan), while the quantitative analyses were performed using flow cytometry (BD FACS Aria III; BD Biosciences, San Jose, CA, USA).

For fluorescence microscopy, 16HBE cells and SH-SY5Y cells were seeded into 24-well plates at a density of 4,000 cells per well and incubated at 37°C in 5% CO₂. On Day 2, the cells were treated with NPs or Lf-NPs containing different concentrations of coumarin-6 for 2 h. Furthermore, the cells were incubated with NPs or Lf-NPs (0.60 μg/mL) for different time intervals. Subsequently, the cells were washed three times with cold PBS and fixed with 4% paraformaldehyde for 10 min. To label the cell nucleus for locating NPs and Lf-NPs within cells, the cells were further incubated with Hoechst 33342 for 10 min. Finally, the cells were washed three times and visualized by fluorescence microscopy.

For flow cytometry, 16HBE cells and SH-SY5Y cells were seeded into six-well plates at a density of 10⁵ cells per well and treated as described earlier. After incubation with NPs or Lf-NPs containing different concentrations of coumarin-6 (0.05–1 μg/mL) for 2 h, the cells were washed three times with cold PBS. Then, cells were trypsinized and centrifuged at 1,500 rpm for 5 min. After resuspension in PBS, the cells were analyzed by flow cytometry.

**In vivo study of NPs and Lf-NPs**

**Brain accumulation of DiR-labeled NPs and Lf-NPs after intranasal administration**

To examine the brain distribution of Lf-NPs and NPs following intranasal administration, in vivo real-time fluorescence imaging analysis (Care stream In Vivo FX; Bruker, Madison, WI, USA) was used. Mice were randomized into three groups and treated with DiR solution, DiR NPs or DiR Lf-NPs as a single dose of 0.25 mg DiR/kg of body weight. Before administration, mice were anesthetized by intraperitoneal injection of chloral hydrate. For intranasal administration, a polyethylene 10 (PE 10) tubing attached to a microliter syringe was inserted ~10 mm deep into the nares. Mice were anesthetized and imaged at 0.5, 1, 2, 4 and 6 h postadministration. To further verify the brain targeting of NPs and Lf-NPs, mice were sacrificed at 4 h postadministration and dissected to obtain the whole brain, heart, liver, spleen, lungs and kidneys. Images were captured with an in vivo imaging system.

**Brain distribution of rotigotine NPs and Lf-NPs following intranasal administration**

Forty mice were randomly divided into two groups for intranasal administration of either rotigotine NPs, as a control group, or rotigotine Lf-NPs. At prespecified time points (0.25, 1, 2, 4 and 8 h), blood samples were obtained by removing the eyeball, and the mice were sacrificed for dissection of the olfactory bulb, striatum, cerebrum with striatum removed and cerebellum. Blood samples were centrifuged at 5,000 rpm for 10 min to collect plasma. Other tissues were homogenized after adding three volumes of saline. To extract the drugs, two volumes of acetonitrile were added to plasma and the tissue homogenates. The concentration of drug was measured via liquid chromatography–tandem mass spectrometry (LC-MS/MS) (AB Sciex Triple Quad™ 4500; Sciex, Framingham, MA, USA) (the LC-MS/MS conditions were as follows: chromatographic column, Shim-pack XR-ODS III C18; mass spectrometer ion source, electrospray ionization source; rotigotine ion pair, 316.0/147.1).

**Statistical analysis**

Data are presented as the mean ± standard deviation (SD). Statistical comparisons were performed using a two-tailed Student’s t-test. Differences were considered statistically significant for a P-value <0.05 and highly significant for a P-value <0.01.

**Results**

**Preparation and characterization of NPs and Lf-NPs**

**Box–Behnken design**

According to the principles of response surface methodology (RSM), using the Box–Behnken design, 29 tests were designed, and the corresponding dependent variables are shown in Table 2. Design-Expert 8.0.6 software was used to perform regression analysis using various indexes, as well as to delineate the interaction between the four independent factors.

Polynomial equations between independent variables and dependent variables were constructed using Design-Expert 8.0.6 software.
Intranasal delivery of rotigotine with lactoferrin-modified PEG-PLGA NPs

The $P$-value of the regression equation for the particle size was $0.0023$ ($P<0.01$), indicating an extremely significant level. Moreover, lack-of-fit analysis ($P=0.2038$) revealed that the equation was a good fit and predictive of the relationship between the factors and particle size. Among the factors, A, B, C and $A^2$ had a significant effect on the particle size.

\[ Y_1 = 55.52 + 20.88A + 15.43B - 13.11C - 6.38D + 14.90AB - 11.95AC - 6.15AD + 3.35BC + 0.65BD + 6.67CD + 14.47A^2 + 10.07B^2 + 10.56C^2 + 5.41D^2 \]

The $P$-value of the regression equation for the entrapment efficiency was significant ($P=0.0303$), whereas the lack of fit was not significant ($P=0.0515$). Factors C, D, AD, $A^2$ and $C^2$ had a significant effect on entrapment efficiency.

Based on real-life clinical practice and trial requirements, particle size tends to be minimum, while the encapsulation efficiency tends to be maximum. The regression model was further processed to determine the level of interaction between the four factors. The impact of the interaction between the various factors on the desirability of encapsulation efficiency and particle size was intuitive, as reflected in Figure 1. The oval and steep slopes in the response surface correspond to a significant interaction between two factors. As indicated by the flag at the highest point of the response surface, the highest response value was within the selected range of each factor.

The optimum formulation of rotigotine NP was selected according to the desired constraints within the range for independent variables, as well as the minimized and maximized constraints for the diameter of particles and entrapment efficiency, respectively. The optimized formulation

Table 2 Effect of independent variables on dependent variables

<table>
<thead>
<tr>
<th>Run</th>
<th>Polymer concentration, mg/mL (A)</th>
<th>W/O ratio (B)</th>
<th>Theoretical drug loading, % (C)</th>
<th>Ice water bath duration, h (D)</th>
<th>Diameter of particles, nm ($Y_1$)</th>
<th>Entrapment efficiency, % ($Y_2$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.50</td>
<td>10.00</td>
<td>5.50</td>
<td>2.00</td>
<td>76.10</td>
<td>84.58</td>
</tr>
<tr>
<td>2</td>
<td>0.85</td>
<td>10.00</td>
<td>10.00</td>
<td>0.00</td>
<td>55.70</td>
<td>42.09</td>
</tr>
<tr>
<td>3</td>
<td>0.85</td>
<td>15.00</td>
<td>5.50</td>
<td>1.00</td>
<td>53.00</td>
<td>88.88</td>
</tr>
<tr>
<td>4</td>
<td>0.85</td>
<td>10.00</td>
<td>5.50</td>
<td>1.00</td>
<td>45.40</td>
<td>90.59</td>
</tr>
<tr>
<td>5</td>
<td>0.85</td>
<td>10.00</td>
<td>5.50</td>
<td>1.00</td>
<td>67.80</td>
<td>84.16</td>
</tr>
<tr>
<td>6</td>
<td>0.20</td>
<td>5.00</td>
<td>5.50</td>
<td>1.00</td>
<td>42.50</td>
<td>88.56</td>
</tr>
<tr>
<td>7</td>
<td>0.85</td>
<td>10.00</td>
<td>1.00</td>
<td>2.00</td>
<td>68.20</td>
<td>104.84</td>
</tr>
<tr>
<td>8</td>
<td>1.50</td>
<td>15.00</td>
<td>5.50</td>
<td>1.00</td>
<td>141.70</td>
<td>27.86</td>
</tr>
<tr>
<td>9</td>
<td>1.50</td>
<td>5.00</td>
<td>5.50</td>
<td>1.00</td>
<td>50.70</td>
<td>58.78</td>
</tr>
<tr>
<td>10</td>
<td>0.85</td>
<td>5.00</td>
<td>10.00</td>
<td>1.00</td>
<td>58.00</td>
<td>73.95</td>
</tr>
<tr>
<td>11</td>
<td>0.85</td>
<td>5.00</td>
<td>5.50</td>
<td>0.00</td>
<td>67.40</td>
<td>85.53</td>
</tr>
<tr>
<td>12</td>
<td>0.85</td>
<td>10.00</td>
<td>10.00</td>
<td>2.00</td>
<td>65.00</td>
<td>81.15</td>
</tr>
<tr>
<td>13</td>
<td>1.50</td>
<td>10.00</td>
<td>10.00</td>
<td>1.00</td>
<td>82.40</td>
<td>36.35</td>
</tr>
<tr>
<td>14</td>
<td>0.20</td>
<td>10.00</td>
<td>1.00</td>
<td>1.00</td>
<td>57.90</td>
<td>25.21</td>
</tr>
<tr>
<td>15</td>
<td>1.50</td>
<td>10.00</td>
<td>5.50</td>
<td>0.00</td>
<td>106.50</td>
<td>44.36</td>
</tr>
<tr>
<td>16</td>
<td>0.85</td>
<td>15.00</td>
<td>1.00</td>
<td>1.00</td>
<td>90.20</td>
<td>103.12</td>
</tr>
<tr>
<td>17</td>
<td>0.85</td>
<td>15.00</td>
<td>10.00</td>
<td>1.00</td>
<td>68.40</td>
<td>54.63</td>
</tr>
<tr>
<td>18</td>
<td>0.85</td>
<td>5.00</td>
<td>1.00</td>
<td>1.00</td>
<td>93.20</td>
<td>79.61</td>
</tr>
<tr>
<td>19</td>
<td>0.20</td>
<td>15.00</td>
<td>5.50</td>
<td>1.00</td>
<td>73.90</td>
<td>54.83</td>
</tr>
<tr>
<td>20</td>
<td>0.85</td>
<td>10.00</td>
<td>5.50</td>
<td>1.00</td>
<td>54.70</td>
<td>79.40</td>
</tr>
<tr>
<td>21</td>
<td>0.20</td>
<td>10.00</td>
<td>5.50</td>
<td>0.00</td>
<td>65.00</td>
<td>61.62</td>
</tr>
<tr>
<td>22</td>
<td>0.85</td>
<td>10.00</td>
<td>5.50</td>
<td>1.00</td>
<td>46.10</td>
<td>88.67</td>
</tr>
<tr>
<td>23</td>
<td>1.50</td>
<td>10.00</td>
<td>1.00</td>
<td>1.00</td>
<td>139.90</td>
<td>102.87</td>
</tr>
<tr>
<td>24</td>
<td>0.85</td>
<td>10.00</td>
<td>1.00</td>
<td>0.00</td>
<td>85.60</td>
<td>42.77</td>
</tr>
<tr>
<td>25</td>
<td>0.85</td>
<td>15.00</td>
<td>5.50</td>
<td>2.00</td>
<td>79.00</td>
<td>102.70</td>
</tr>
<tr>
<td>26</td>
<td>0.20</td>
<td>10.00</td>
<td>10.00</td>
<td>1.00</td>
<td>48.20</td>
<td>74.23</td>
</tr>
<tr>
<td>27</td>
<td>0.20</td>
<td>10.00</td>
<td>5.50</td>
<td>2.00</td>
<td>59.20</td>
<td>108.88</td>
</tr>
<tr>
<td>28</td>
<td>0.85</td>
<td>10.00</td>
<td>5.50</td>
<td>1.00</td>
<td>63.60</td>
<td>102.44</td>
</tr>
<tr>
<td>29</td>
<td>0.85</td>
<td>5.00</td>
<td>5.50</td>
<td>2.00</td>
<td>50.00</td>
<td>104.82</td>
</tr>
</tbody>
</table>

Abbreviation: W/O, water-organic phase.
Figure 1: Three-dimensional response surface plots showing the effect of independent variables on dependent variables.

Notes: The Y-axis represents the desirability of dependent variables. The flag represents the site of the optimal formulation. 

was 1.44±0.02, which was within the optimal range of 1–2. Lf conjugation efficiency was 18.99%±2.32%.

In vitro drug release study
The in vitro drug release kinetics of rotigotine from rotigotine NPs and Lf-NPs was evaluated in PBS (pH 7.4) at 37°C. As depicted in Figure 3, free rotigotine was rapidly released from the dialysis bag within 4 h (73.0%±5.4%). With respect to the NP formulation, drug release was rapid during the first 0.5 h (surface desorption, diffusion and dissolution). Thereafter, a prolonged and sustained release without burst was observed for NPs (81.3%±2.1%) and Lf-NPs (77.8%±7.0%) for 48 h, which can provide CDS for the treatment of PD.

Cellular studies of NPs and Lf-NPs
Following intranasal administration of NPs, the nasal epithelial cells were exposed, followed by nerve cells in the brain. To emulate these conditions and to evaluate the safety and uptake capacity of NPs and Lf-NPs, the 16HBE cell line and SH-SY5Y cell line were used.

Cytotoxicity studies of NPs and Lf-NPs
To assess the toxicity of NPs after intranasal administration and the brain-targeting activity, NPs/Lf-NPs, either loaded with rotigotine or unloaded, were incubated with 16HBE cells and SH-SY5Y cells. Cell viability was evaluated after 24 h and 48 h by the MTT assay. Unloaded NPs and Lf-NPs were nontoxic to 16HBE and SH-SY5Y cells at all concentrations tested (data not shown). Moreover, as shown in Figure 4, rotigotine solution, rotigotine NPs and rotigotine Lf-NPs did not cause significant cell death at lower concentrations (12.5–50 μg/mL). However, exposure to higher

Table 3 Characterization of rotigotine NPs and Lf-NPs

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Particle size, nm</th>
<th>Polydispersity index</th>
<th>Zeta potential, mV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rotigotine NPs</td>
<td>58.1±6.2</td>
<td>0.137±0.038</td>
<td>−20.44±0.31</td>
</tr>
<tr>
<td>Rotigotine Lf-NPs</td>
<td>122.0±19.3</td>
<td>0.194±0.023</td>
<td>−21.28±2.15</td>
</tr>
</tbody>
</table>

Abbreviations: Lf-NPs, lactoferrin-modified nanoparticles; NPs, nanoparticles.

Figure 2 Transmission electron microscopy images of (A) rotigotine NPs and (B) rotigotine Lf-NPs.
Abbreviations: Lf-NPs, lactoferrin-modified nanoparticles; NPs, nanoparticles.
concentrations (100 μg/mL and 200 μg/mL) of free rotigotine for 24 h and 48 h resulted in a decrease ($P<0.05$) in cell viability compared with the same concentration of rotigotine NPs/Lf-NPs, which indicated that the toxicity of rotigotine was reduced when encapsulated in PLGA NPs. There was no significant difference between rotigotine NPs and rotigotine Lf-NPs in terms of toxicity, suggesting the safety of Lf.

Cellular uptake of coumarin-6-labeled NPs and Lf-NPs
Cellular association of coumarin-6-labeled NPs and Lf-NPs in 16HBE and SH-SY5Y cells was qualitatively measured using fluorescence microscope images (Figure 5). At all the tested concentrations and time points, cellular uptake of Lf-NPs was markedly higher than that of NPs. The same result was obtained from quantitative analysis by flow cytometry (Figure 6A), in which the mean fluorescence intensity of Lf-NPs was higher than that of NPs ($P<0.05$) in the experimental concentration range (0.05–1 μg/mL). This indicated that Lf modification enhanced the penetration and targeting of NPs, presumably because the Lf receptor is expressed on the surface of the two cell types.

Figure 5 shows that the intensity of fluorescence was increased after incubation with increasing concentrations/times.

**Figure 3** In vitro release studies of rotigotine from free rotigotine, rotigotine NPs and rotigotine Lf-NPs.
*Note:* Values represent the mean ± SD (n=3).
*Abbreviations:* Lf-NPs, lactoferrin-modified nanoparticles; NPs, nanoparticles.

**Figure 4** In vitro cytotoxicity of free rotigotine, rotigotine NPs and rotigotine Lf-NPs.
*Notes:* In vitro cytotoxicity in (A) 16HBE and (B) SH-SY5Y cells. Significant differences between rotigotine NPs/Lf-NPs and free rotigotine are marked with * for $P<0.05$ and ** for $P<0.01$. Values represent the mean ± SD (n=4).
*Abbreviations:* Lf-NPs, lactoferrin-modified nanoparticles; NPs, nanoparticles.
of NPs. The time- and concentration-dependent uptake pattern was indicative of an active endocytic process.\textsuperscript{24} NPs were rapidly internalized by 16HBE cells, suggesting that they were rapidly absorbed after intranasal administration. Intracellular localization of NPs was visualized by confocal microscopy. As shown in Figure 6B and C, coumarin-6-labeled NPs and Lf-NPs were observed surrounding (but not colocalized with) the nuclei, reflecting the uptake of Lf-NPs into the cytoplasm of 16HBE and SH-SY5Y cells.

**In vivo brain accumulation of DiR-labeled NPs and Lf-NPs after intranasal administration**

Figure 7A shows the in vivo fluorescence images from mice at predefined times after intranasal administration of DiR-labeled Lf-NPs and NPs. A weak signal was observed in the free DiR group, which was attributed to the DiR remaining in the nasal cavity. However, there was a gradual increase in signal intensity, with the maximum
Brain distribution of rotigotine NPs and Lf-NPs following intranasal administration

The brain distribution of rotigotine NPs was quantitatively analyzed in mice following intranasal administration. As shown in Figure 8A, plasma concentration–time curves of Lf-NPs and NPs had similar trends, which suggested that the Lf modification on the surface of NPs did not impair the long circulation time of PEG. After intranasal administration of rotigotine NPs/Lf-NPs, the concentration of rotigotine was much higher in the striatum than in plasma, and the area under the concentration–time curve for 0–8 h (AUC$_{0-8h}$) for NPs and Lf-NPs was 1.44- and 1.89-fold higher in the striatum compared with that in the plasma, indicating that intranasal administration may contribute to more efficient brain drug delivery.
In addition, rotigotine was detected in the striatum for 8 h, suggesting that drug delivery was slow and constant, which would facilitate CDS for the treatment of PD.

The $AUC_{0-8\text{ h}}$ and the maximum plasma concentration ($C_{\text{max}}$) values were higher for Lf-NPs than for unconjugated NPs in all four brain tissues, with the $AUC_{0-8\text{ h}}$ of Lf-NPs being 1.21-, 1.31-, 1.93- and 1.24-fold higher in the olfactory bulb, striatum, cerebrum with striatum removed, and cerebellum, respectively. These results indicated that Lf-NPs enabled intranasal transport, thereby increasing brain drug concentrations, which may be attributed to the interaction between Lf and LfR on respiratory epithelial cells and brain cells.
As shown in Figure 8B and C, the concentration of rotigotine in the different brain regions was variable. The high concentration of rotigotine in the striatum, which is the main site of lesions in PD, indicated that intranasal NPs administration may be promising for the treatment of PD. In addition, the high concentration of rotigotine in the olfactory bulb suggested that NPs may be directly transported to the brain via both the olfactory and the trigeminal nerve pathways.

**Conclusion**

In this study, we successfully established a novel nose-to-brain drug delivery system using modified biodegradable PEG-PLGA NPs with Lf, a useful targeting molecule. The NPs exhibited a spherical shape, small particle size, narrow size distribution and negative potential. The in vitro cytotoxicity of the unloaded and rotigotine-loaded NPs was low. Cellular uptake experiments showed that Lf-NPs exhibited enhanced cellular accumulation compared with unmodified NPs. Conjugation of Lf was favorable for rotigotine delivery in the olfactory bulb, striatum, cerebrum with striatum removed, and cerebellum. These results confirmed that this drug delivery system could offer a promising non-invasive approach for the treatment of PD.

**Acknowledgment**

This study was funded by the National Science and Technology Foundation (2013ZX09402201) and the Natural Science Foundation of Shandong Province (ZR2013HQ009).

**Disclosure**

The authors report no conflicts of interest in this work.
Intranasal delivery of rotigotine with lactoferrin-modified PEG-PLGA NPs

References